Literature DB >> 17662013

Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event.

R Schneider1, B Euler, S Rauer.   

Abstract

The objective of this study was to investigate, whether the presence of oligoclonal immunoglobulin M bands (IgM-OCB) in cerebrospinal fluid (CSF) from patients with a clinically isolated syndrome (CIS), which is suggestive for the first clinical manifestation of multiple sclerosis (MS), anticipates the risk of a relapse during a retrospective study period of 21-106 months (mean 60 +/- 25). A relapse would lead to the diagnosis of clinically definite MS. Paired CSF and serum samples from 42 patients with a CIS and positive intrathecal IgG-synthesis were tested retrospectively for IgM-OCB, which are exclusively present in CSF, but not in the corresponding serum. Isoelectric focusing and affinity blot were used and clinical follow-up was based on telephone interviews. IgM-OCB were found in the CSF from 31 of 42 patients (74%). There was no correlation between the presence of IgM-OCB, the number of such bands or the IgM-Index on the one hand and the risk of a relapse during the follow-up in the cohort studied, on the other hand. These data do not support the idea that the presence of IgM-OCB in CSF might predict an unfavourable course in MS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17662013     DOI: 10.1111/j.1468-1331.2007.01871.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  8 in total

1.  Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Authors:  Jessica Frau; Luisa Maria Villar; Claudia Sardu; Maria Antonietta Secci; Lucia Schirru; Diana Ferraro; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Roberta Bedin; Patrizia Sola; Maria Giovanna Marrosu; Eleonora Cocco
Journal:  J Neurol       Date:  2017-12-22       Impact factor: 4.849

Review 2.  Body fluid biomarkers in multiple sclerosis: how far we have come and how they could affect the clinic now and in the future.

Authors:  Itay Raphael; Johanna Webb; Olaf Stuve; William Haskins; Thomas Forsthuber
Journal:  Expert Rev Clin Immunol       Date:  2014-12-18       Impact factor: 4.473

3.  IL-2, IL-6 and chitinase 3-like 2 might predict early relapse activity in multiple sclerosis.

Authors:  Marko Petržalka; Eva Meluzínová; Jana Libertínová; Hana Mojžišová; Jitka Hanzalová; Petra Ročková; Martin Elišák; Silvia Kmetonyová; Jan Šanda; Ondřej Sobek; Petr Marusič
Journal:  PLoS One       Date:  2022-06-27       Impact factor: 3.752

Review 4.  The Cerebrospinal Fluid in Multiple Sclerosis.

Authors:  Florian Deisenhammer; Henrik Zetterberg; Brit Fitzner; Uwe K Zettl
Journal:  Front Immunol       Date:  2019-04-12       Impact factor: 7.561

5.  Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis.

Authors:  Igal Rosenstein; Sofia Rasch; Markus Axelsson; Lenka Novakova; Kaj Blennow; Henrik Zetterberg; Jan Lycke
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

6.  Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.

Authors:  Ralf A Linker; Peter Brechlin; Sarah Jesse; Petra Steinacker; D H Lee; Abdul R Asif; Olaf Jahn; Hayrettin Tumani; Ralf Gold; Markus Otto
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

7.  Biomarkers in Multiple Sclerosis: An Up-to-Date Overview.

Authors:  Serafeim Katsavos; Maria Anagnostouli
Journal:  Mult Scler Int       Date:  2013-01-22

8.  Cerebrospinal Fluid IgM Levels in Association With Inflammatory Pathways in Multiple Sclerosis Patients.

Authors:  Roberta Magliozzi; Valentina Mazziotti; Luigi Montibeller; Anna I Pisani; Damiano Marastoni; Agnese Tamanti; Stefania Rossi; Francesco Crescenzo; Massimiliano Calabrese
Journal:  Front Cell Neurosci       Date:  2020-10-16       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.